WO2023022613A3 - Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto - Google Patents

Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto Download PDF

Info

Publication number
WO2023022613A3
WO2023022613A3 PCT/PH2022/050014 PH2022050014W WO2023022613A3 WO 2023022613 A3 WO2023022613 A3 WO 2023022613A3 PH 2022050014 W PH2022050014 W PH 2022050014W WO 2023022613 A3 WO2023022613 A3 WO 2023022613A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulins
epitopes
producing
antipeptide
cov
Prior art date
Application number
PCT/PH2022/050014
Other languages
French (fr)
Other versions
WO2023022613A2 (en
Inventor
Salvador Eugenio CAOILI
Ruby Anne KING
Fresthel Monica CLIMACOSA
Riziel Hannah AGUIMATANG
Ayra Patrice ESPIRITU
Original Assignee
University Of The Philippines Manila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of The Philippines Manila filed Critical University Of The Philippines Manila
Publication of WO2023022613A2 publication Critical patent/WO2023022613A2/en
Publication of WO2023022613A3 publication Critical patent/WO2023022613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides: antipeptide immunoglobulins recognizing epitopes within the subdomain SD2 major disulfide loop of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S protein); cognate oligopeptide-based immunogenic constructs comprising said epitopes; methods for producing said immunoglobulins and said constructs; methods and systems for detecting antigens comprising said epitopes; use of said constructs for producing said immunoglobulins; and use of said immunoglobulins for detecting said antigens.
PCT/PH2022/050014 2021-08-13 2022-08-13 Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto WO2023022613A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PH12021050442 2021-08-13
PH12021050442 2021-08-13

Publications (2)

Publication Number Publication Date
WO2023022613A2 WO2023022613A2 (en) 2023-02-23
WO2023022613A3 true WO2023022613A3 (en) 2023-03-30

Family

ID=85241155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PH2022/050014 WO2023022613A2 (en) 2021-08-13 2022-08-13 Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto

Country Status (1)

Country Link
WO (1) WO2023022613A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3007090A1 (en) * 2014-10-09 2016-04-13 Strelnikov, Evgeny Immunogenic synthetic oligopeptides
WO2021138721A1 (en) * 2020-01-09 2021-07-15 The University Of Queensland Self-assembling, self-adjuvanting system for delivery of vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3007090A1 (en) * 2014-10-09 2016-04-13 Strelnikov, Evgeny Immunogenic synthetic oligopeptides
WO2021138721A1 (en) * 2020-01-09 2021-07-15 The University Of Queensland Self-assembling, self-adjuvanting system for delivery of vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEFFRON ANNA S., MCILWAIN SEAN J., AMJADI MAYA F., BAKER DAVID A., KHULLAR SANIYA, ARMBRUST TAMMY, HALFMANN PETER J., KAWAOKA YOSH: "The landscape of antibody binding in SARS-CoV-2 infection", PLOS BIOLOGY, vol. 19, no. 6, pages e3001265, XP093056719, DOI: 10.1371/journal.pbio.3001265 *
MAHENDRAN ARUN SURIA KARNAN, LIM YIN SZE, FANG CHEE-MUN, LOH HWEI-SAN, LE CHENG FOH: "The Potential of Antiviral Peptides as COVID-19 Therapeutics", FRONTIERS IN PHARMACOLOGY, vol. 11, XP055796673, DOI: 10.3389/fphar.2020.575444 *
MOROY G., TUFFERY P.: "Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective", FRONTIERS IN DRUG DISCOVERY, vol. 2, XP093056716, DOI: 10.3389/fddsv.2022.899477 *

Also Published As

Publication number Publication date
WO2023022613A2 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
HK1026911A1 (en) Novel method for the production of antihuman antigen receptors and uses thereof
NO20063478L (en) Neutralizing epitope-based growth-promoting vaccine
MY162525A (en) Process for concentration of antibodies and therapeutic products thereof
BR0111823A (en) Polypeptide, vaccine, method for immunizing an animal against a pathogen, method for identifying antigenic polypeptide, antibody, or at least an effective part thereof, vector, cell, method for producing antibody, hybridoma cell line, and, use of antibodies.
EP4356924A3 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
AU2002355677A1 (en) Antigenic polypeptides
DE602006013428D1 (en) CHIMAIR RECOMBINANT ANTIGENS OF TOXOPLASMA GONDII
MX2020009825A (en) Precision glycoconjugates as therapeutic tools.
MX2023004054A (en) Anti-dectin-1 antibodies and methods of use thereof.
NO20081043L (en) Vaccine for fish
EA201290961A1 (en) METHODS OF APPLICATION OF SOLUBLE CD24 FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
AU2018388102A1 (en) Cross-immunizing antigen vaccine and method for preparation thereof
WO2023022613A3 (en) Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto
Verch et al. Immunization with a plant-produced colorectal cancer antigen
Yan et al. Heterosubtypic protection induced by a live attenuated influenza virus vaccine expressing galactose-α-1, 3-galactose epitopes in infected cells
MX2022004058A (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof.
DE60216906T8 (en) ANTI-PILYROSPORUM OVALE IGY AND ITS USE
AR076083A1 (en) ANTI-RHESUS D MONOCLONAL ANTIBODY
WO2022047176A3 (en) Single-chain coronavirus viral membrane protein complexes
Ibañez et al. Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains
MX2022016494A (en) Anti-il13rî±2 antibodies.
WO2009137632A3 (en) Hiv immunogen and method of making and using same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22858831

Country of ref document: EP

Kind code of ref document: A2